IDEAYA Biosciences, Inc.
IDYA
$19.13
$0.552.96%
| Weiss Ratings | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.40 | |||
| Price History | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.31% | |||
| 30-Day Total Return | -21.44% | |||
| 60-Day Total Return | -26.56% | |||
| 90-Day Total Return | -33.11% | |||
| Year to Date Total Return | -23.97% | |||
| 1-Year Total Return | -56.82% | |||
| 2-Year Total Return | 23.50% | |||
| 3-Year Total Return | 60.89% | |||
| 5-Year Total Return | 474.47% | |||
| 52-Week High % Change | -59.96% | |||
| 52-Week Low % Change | 9.62% | |||
| Price | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $46.40 | |||
| 52-Week Low Price | $16.95 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Mar 21, 2024 | |||
| Valuation | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.63B | |||
| Enterprise Value | 563.46M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.30 | |||
| Earnings Per Share Growth | 67.97% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 231.96 | |||
| Price/Book (Q) | 1.52 | |||
| Enterprise Value/Revenue (TTM) | 80.49 | |||
| Price | $19.13 | |||
| Enterprise Value/EBITDA (TTM) | -1.74 | |||
| Enterprise Value/EBIT | -1.72 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 87.34M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 443 6209 | |||
| Address | 5000 Shoreline Court South San Francisco, CA 94080 | |||
| Website | www.ideayabio.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -4,671.07% | |||
| Profit Margin | -3,921.10% | |||
| Management Effectiveness | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -23.05% | |||
| Return on Equity | -- | |||
| Income Statement | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 7.00M | |||
| Total Revenue (TTM) | 7.00M | |||
| Revenue Per Share | $0.08 | |||
| Gross Profit (TTM) | -287.67M | |||
| EBITDA (TTM) | -324.59M | |||
| EBIT (TTM) | -326.98M | |||
| Net Income (TTM) | -274.48M | |||
| Net Income Avl. to Common (TTM) | -274.48M | |||
| Total Revenue Growth (Q YOY) | 78.48% | |||
| Earnings Growth (Q YOY) | -283.78% | |||
| EPS Diluted (TTM) | -3.30 | |||
| EPS Diluted Growth (Q YOY) | -186.70% | |||
| Balance Sheet | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 676.32M | |||
| Cash Per Share (Q) | $7.74 | |||
| Total Current Assets (Q) | 689.71M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.06B | |||
| Current Ratio (Q) | 14.971 | |||
| Book Value Per Share (Q) | $12.24 | |||
| Total Assets (Q) | 1.12B | |||
| Total Current Liabilities (Q) | 46.07M | |||
| Total Debt (Q) | 19.17M | |||
| Total Liabilities (Q) | 64.94M | |||
| Total Common Equity (Q) | 1.06B | |||
| Cash Flow | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -502.56M | |||
| Cash from Financing (TTM) | 677.55M | |||
| Net Change in Cash (TTM) | -72.59M | |||
| Levered Free Cash Flow (TTM) | -160.97M | |||
| Cash from Operations (TTM) | -247.58M | |||
